Verona Pharma Company Insiders
VRNA Stock | USD 38.81 0.95 2.51% |
About 90 percent of Verona Pharma's insiders are activelly selling. The analysis of insiders' sentiment of trading Verona Pharma PLC stock suggests that a very large number of insiders are panicking at this time. Verona Pharma employs about 79 people. The company is managed by 17 executives with a total tenure of roughly 185 years, averaging almost 10.0 years of service per executive, having 4.65 employees per reported executive.
Verona Pharma's Insider Buying Vs Selling
10
Selling | Buying |
Latest Trades
2024-11-11 | David Zaccardelli | Disposed 2400 @ 5 | View | ||
2024-11-06 | David R Ebsworth | Acquired 39360 @ 4.8 | View | ||
2024-11-04 | Mark W Hahn | Disposed 80784 @ 4.39 | View | ||
2024-11-01 | Mark W Hahn | Disposed 48888 @ 4.38 | View | ||
2024-10-25 | David Zaccardelli | Disposed 4800 @ 4.38 | View | ||
2024-10-24 | Mark W Hahn | Disposed 141360 @ 4.38 | View | ||
2024-10-23 | David Zaccardelli | Disposed 16 @ 4.38 | View | ||
2024-10-21 | Mark W Hahn | Disposed 116696 @ 4.38 | View | ||
2024-10-18 | Mark W Hahn | Disposed 249728 @ 4.38 | View | ||
2024-05-03 | Kathleen A Rickard | Disposed 36248 @ 1.96 | View |
Monitoring Verona Pharma's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Verona |
Verona Pharma's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Verona Pharma's future performance. Based on our forecasts, it is anticipated that Verona will maintain a workforce of about 80 employees by December 2024.Verona Pharma Management Team Effectiveness
The company has return on total asset (ROA) of (0.2805) % which means that it has lost $0.2805 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7803) %, meaning that it created substantial loss on money invested by shareholders. Verona Pharma's management efficiency ratios could be used to measure how well Verona Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of November 25, 2024, Return On Tangible Assets is expected to decline to -0.19. In addition to that, Return On Capital Employed is expected to decline to -0.24. At present, Verona Pharma's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 19.3 M, whereas Return On Tangible Assets are forecasted to decline to (0.19).As of November 25, 2024, Common Stock Shares Outstanding is expected to decline to about 75.3 M. The current year's Net Loss is expected to grow to about (58.7 M)
Verona Pharma Workforce Comparison
Verona Pharma PLC is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 3,287. Verona Pharma holds roughly 79.0 in number of employees claiming about 2.4% of equities under Health Care industry.
Verona Pharma Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Verona Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Verona Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Verona Pharma insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-12-01 | 0.5 | 10 | 20 | 2,751,240 | 2,162,640 |
2024-09-01 | 0.2857 | 4 | 14 | 1,836,000 | 3,000,824 |
2024-06-01 | 2.5 | 10 | 4 | 4,560,000 | 287,160 |
2024-03-01 | 0.3333 | 2 | 6 | 260,592 | 1,289,880 |
2023-12-01 | 1.1667 | 7 | 6 | 2,389,832 | 2,219,904 |
2023-09-01 | 0.0909 | 2 | 22 | 233,976 | 1,194,680 |
2023-06-01 | 0.7333 | 11 | 15 | 887,328 | 2,086,770 |
2023-03-01 | 0.3333 | 3 | 9 | 435,800 | 1,466,336 |
2022-12-01 | 0.05 | 1 | 20 | 170,000 | 14,930,520 |
2022-09-01 | 0.4 | 4 | 10 | 13,290,104 | 2,410,976 |
2022-06-01 | 1.5556 | 14 | 9 | 2,690,104 | 1,247,312 |
2022-03-01 | 0.5 | 4 | 8 | 846,328 | 884,664 |
2021-12-01 | 0.125 | 1 | 8 | 90,104 | 1,210,768 |
2021-09-01 | 1.1 | 11 | 10 | 1,000,400 | 1,891,560 |
2021-03-01 | 0.0909 | 3 | 33 | 750,928 | 2,815,120 |
Verona Pharma Notable Stakeholders
A Verona Pharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Verona Pharma often face trade-offs trying to please all of them. Verona Pharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Verona Pharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
David PharmD | CEO President | Profile | |
Caroline Diaz | Senior Affairs | Profile | |
LCSW BA | G Counsel | Profile | |
Matthew Casbon | Marketing Sales | Profile | |
Peter Spargo | Senior Controls | Profile | |
Kathleen MD | Chief Officer | Profile | |
B ASIA | General Counsel | Profile | |
Kavita Aggarwal | Senior Affairs | Profile | |
Christopher Martin | Chief Officer | Profile | |
Nina Church | Ex Devel | Profile | |
Tara MPH | Chief Officer | Profile | |
David Zaccardelli | CEO Pres | Profile | |
Mark Hahn | Chief Officer | Profile | |
Kathleen Rickard | Chief Officer | Profile | |
Victoria Stewart | Director Communications | Profile | |
Ostra Jewell | Senior Resources | Profile | |
Andrew Fisher | General Counsel | Profile |
About Verona Pharma Management Performance
The success or failure of an entity such as Verona Pharma PLC often depends on how effective the management is. Verona Pharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Verona management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Verona management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.18) | (0.19) | |
Return On Capital Employed | (0.23) | (0.24) | |
Return On Assets | (0.18) | (0.19) | |
Return On Equity | (0.22) | (0.23) |
Please note, the presentation of Verona Pharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Verona Pharma's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Verona Pharma's management manipulating its earnings.
Verona Pharma Workforce Analysis
Traditionally, organizations such as Verona Pharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Verona Pharma within its industry.Verona Pharma Manpower Efficiency
Return on Verona Pharma Manpower
Revenue Per Employee | 5.8K | |
Revenue Per Executive | 26.9K | |
Net Loss Per Employee | 690.9K | |
Net Loss Per Executive | 3.2M | |
Working Capital Per Employee | 3.6M | |
Working Capital Per Executive | 16.5M |
Complementary Tools for Verona Stock analysis
When running Verona Pharma's price analysis, check to measure Verona Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Verona Pharma is operating at the current time. Most of Verona Pharma's value examination focuses on studying past and present price action to predict the probability of Verona Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Verona Pharma's price. Additionally, you may evaluate how the addition of Verona Pharma to your portfolios can decrease your overall portfolio volatility.
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |